MANCHESTER, NH -- (Marketwired) -- 03/27/15 -- Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate chemistry, has reported its financial results for the fourth quarter and fiscal year ended December 31, 2014 and provided a corporate update.

Boston Therapeutics and Advance Pharmaceutical Company (APC) announced today the expansion of their sugardown® licensing agreement to Japan, a move that increases the number of Asian countries covered by the agreement to 16. Advance Pharmaceutical further reiterated its commitment to collaborate with Boston Therapeutics for funding of clinical trials for sugardown®. Upcoming product development trials are expected to include a pre-diabetes study of sugardown® at the Chinese University of Hong Kong and a U.S. Phase II study at the Joslin Diabetes Center in Boston for Boston Therapeutics’ BTI-320 candidate (a new generation of alpha glucosidase inhibitor that is designed to reduce post-meal elevation of blood glucose).